$1.730
-0.029 (-1.70%)Zum Schluss
ZYBT-News
ZYBT-Events
Zhengye Biotechnology Holding Ltd Trading Halted
Zhengye Biotechnology Holding Ltd trading halted, volatility trading pause
Zhengye Biotechnology Responds to Unusual Trading Activity
Zhengye Biotechnology issued the following statement in response to recent unusual trading activity in the price and trading volume of its Class A ordinary shares. "The Company does not normally comment on market activity or rumors. However, in light of the magnitude of the recent trading activity in the Company's securities, the Company is providing the following statement. The Company confirms that it is not aware of any material non-public information regarding the Company, its business, financial condition, or operations that would account for the recent increase in trading activity in its securities. The Company's business operations continue in the ordinary course, and there have been no undisclosed corporate developments, transactions, or events that management believes would explain the recent price or volume movements. The Company has been in contact with Nasdaq regarding the recent increase in trading volume of the shares of the Company and will continue to cooperate with Nasdaq and other relevant regulatory authorities as appropriate. Shareholders and prospective investors are cautioned to exercise care when evaluating the Company's securities in light of the recent volatility and to rely only on information contained in the Company's filings with the U.S. Securities and Exchange Commission."
Zhengye Biotechnology Receives Nasdaq Non-Compliance Notice
Zhengye Biotechnology announced that on May 29, the company received a written notification from the Nasdaq Stock Market indicating that it is not in compliance with the minimum bid price requirement. The deficiency resulted from the closing bid price of the company's Class A ordinary shares being below $1.00 per share for 30 consecutive business days. Zhengye has 180 calendar days, or until November 25 to regain compliance. Its business operations are currently unaffected by the notice.
Zhengye Biotechnology Chairman's Letter to Shareholders Outlines Vision for 2026
Zhengye Biotechnology announced that Zhenfa Han, Chairman of the Board of Directors of Zhengye, has issued a letter to shareholders. "As we enter 2026, on behalf of the management of Zhengye Biotechnology Holding Limited, I am proud of the milestones we achieved in 2025 and would like to share our strategic vision for 2026 and the years ahead... Core Achievements in 2025: A Year of Strategic Execution and Innovation... Over the past year, we focused on strengthening our innovation capabilities, advancing regulatory milestones, and building operational excellence to capture opportunities in an evolving industry landscape. What guided us through these efforts was our unwavering commitment to becoming a world-leading manufacturer that delivers reliable veterinary vaccines to customers around the world. Every patent filed, every regulatory approval earned, and every capability enhanced represents a deliberate investment in our future competitiveness and our ability to better serve our customers... As we look to 2026, we are encouraged by the signs of gradual recovery of China's swine market, with industry expectations for a price inflection point around mid-year. More importantly, the capabilities we have built, our expanded product portfolio, strengthened international presence, and enhanced operational platforms provide a solid foundation for our next stage of growth. Building on our foundation, we plan to focus on the following strategic priorities: 1. Deepening Strategic Customer Engagement... 2. Strengthening Product Portfolio with Solution-Based Marketing... 3. Building an Empowering Customer Service Ecosystem... 4. Strategic Expansion into Companion Animal Sector... Together, we intend to continue to advance innovation and growth, and remain firmly committed to delivering sustainable, long-term value for our shareholders."
Zhengye Biotechnology opens at $3.77, IPO priced at $4.00
Zhengye Biotechnology, a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccine in China, priced its initial public offering of 1.5M shares at a public offering price of $4.00. The shares are listed on the Nasdaq under the ticker symbol "ZYBT." Kingswood Capital Partners is acting as the sole book-running manager for the offering.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.